Stay updated on Seagen Press Releases
Sign up to get notified when there's something new on the Seagen Press Releases page.

Latest updates to the Seagen Press Releases page
- Check4 days agoChange DetectedFour May 2026 press releases were added to the Newsroom, covering TALZENNA Plus XTANDI results in metastatic prostate cancer, LORBRENA CROWN trial results in advanced NSCLC, a global collaboration with Innovent Biologics to accelerate oncology medicines, and an investor webcast invitation.SummaryDifference8%

- Check11 days agoChange DetectedAdds a new press release entry titled 'Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results' dated 05.20.2026 under the Research and Pipeline category, expanding the page's current press listings. Removes 'Pfizer logo' and 'Finance' items from navigation/branding areas.SummaryDifference3%

- Check18 days agoChange DetectedA new HYMPAVZI press release is added to the May 2026 list, and the TALZENNA Plus XTANDI entry is removed from March 2026. The page header branding now includes the Pfizer logo and a branded tagline.SummaryDifference3%

- Check25 days agoChange DetectedAdded a May 5, 2026 press release entry for Pfizer's first-quarter results and reaffirmed 2026 guidance, and removed the March 17, 2026 press release from the listing along with the 'Research' and 'Research and Pipeline' categories.SummaryDifference1%

- Check32 days agoChange DetectedNew April 2026 press releases were added—'Pfizer Reaches Three Settlement Agreements for VYNDAMAX' and 'Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma'—and the category labels now include Finance, Corporate, and Prescription Medicines, while an older release was removed from the list.SummaryDifference4%

- Check40 days agoChange DetectedUpdated the press release listings by adding several new April 2026 items (including Pfizer’s 2026 shareholder meeting preliminary results, a second-quarter dividend announcement, and FDA priority review for PADCEV™ + Keytruda®) and removing a set of older February 2026 press releases.SummaryDifference8%

Stay in the know with updates to Seagen Press Releases
Enter your email address, and we'll notify you when there's something new on the Seagen Press Releases page.